Ferronova, founded in 2016 and headquartered in Australia, is a promising company in the Biotechnology, Health Care, and Medical Devices sectors. Committed to their slogan, "To give everyone diagnosed with cancer their best chance to become cancer free," Ferronova has developed an advanced diagnostic system for detecting cancer metastases. This innovation merges a patented magnetic probe from the University of South Australia with cutting-edge iron magnetic nanoparticle technology from Victoria University of Wellington.
The company collaborates with notable research institutions, including UniSA Future Industries Institute, University of Sydney, and University of New South Wales. Its notable backers include Uniseed, Artesian Ventures, Powerhouse Ventures, PAN Ventures, UniSA Ventures, and Wellington UniVentures, along with financial support from the South Australian and Australian governments.
In January 2023, Ferronova secured a $8.00M Series B investment from Artesian, Uniseed, and Renew Pharmaceuticals, marking a significant milestone in its growth trajectory.